[ad_1] Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on clinical programs expected in 2024 $349.7 million in cash, cash equivalents,…
[ad_1] Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer Enrollment ongoing for EGFR-TRACTr (JANX008) in solid tumors Update on clinical programs expected in 2024 $349.7 million in cash, cash equivalents,…